Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

750 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.
Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC; Children's Oncology Group Pilot Study. Raetz EA, et al. Among authors: goldenberg dm. J Clin Oncol. 2008 Aug 1;26(22):3756-62. doi: 10.1200/JCO.2007.15.3528. J Clin Oncol. 2008. PMID: 18669463 Free PMC article. Clinical Trial.
Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
Leonard JP, Coleman M, Ketas J, Ashe M, Fiore JM, Furman RR, Niesvizky R, Shore T, Chadburn A, Horne H, Kovacs J, Ding CL, Wegener WA, Horak ID, Goldenberg DM. Leonard JP, et al. Among authors: goldenberg dm. J Clin Oncol. 2005 Aug 1;23(22):5044-51. doi: 10.1200/JCO.2005.13.821. Epub 2005 Jun 13. J Clin Oncol. 2005. PMID: 15955901 Clinical Trial.
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
Strauss SJ, Morschhauser F, Rech J, Repp R, Solal-Celigny P, Zinzani PL, Engert A, Coiffier B, Hoelzer DF, Wegener WA, Teoh NK, Goldenberg DM, Lister TA. Strauss SJ, et al. Among authors: goldenberg dm. J Clin Oncol. 2006 Aug 20;24(24):3880-6. doi: 10.1200/JCO.2006.05.6291. Epub 2006 Jul 24. J Clin Oncol. 2006. PMID: 16864854 Clinical Trial.
Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.
Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll WL. Raetz EA, et al. Among authors: goldenberg dm. Pediatr Blood Cancer. 2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2. Pediatr Blood Cancer. 2015. PMID: 25732247 Free PMC article. Clinical Trial.
Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM. Leonard JP, et al. Among authors: goldenberg dm. Clin Cancer Res. 2004 Aug 15;10(16):5327-34. doi: 10.1158/1078-0432.CCR-04-0294. Clin Cancer Res. 2004. PMID: 15328168 Clinical Trial.
High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.
Morschhauser F, Kraeber-Bodéré F, Wegener WA, Harousseau JL, Petillon MO, Huglo D, Trümper LH, Meller J, Pfreundschuh M, Kirsch CM, Naumann R, Kropp J, Horne H, Teoh N, Le Gouill S, Bodet-Milin C, Chatal JF, Goldenberg DM. Morschhauser F, et al. Among authors: goldenberg dm. J Clin Oncol. 2010 Aug 10;28(23):3709-16. doi: 10.1200/JCO.2009.27.7863. Epub 2010 Jul 12. J Clin Oncol. 2010. PMID: 20625137 Clinical Trial.
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
Bardia A, Mayer IA, Diamond JR, Moroose RL, Isakoff SJ, Starodub AN, Shah NC, O'Shaughnessy J, Kalinsky K, Guarino M, Abramson V, Juric D, Tolaney SM, Berlin J, Messersmith WA, Ocean AJ, Wegener WA, Maliakal P, Sharkey RM, Govindan SV, Goldenberg DM, Vahdat LT. Bardia A, et al. Among authors: goldenberg dm. J Clin Oncol. 2017 Jul 1;35(19):2141-2148. doi: 10.1200/JCO.2016.70.8297. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291390 Free PMC article. Clinical Trial.
Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.
Heist RS, Guarino MJ, Masters G, Purcell WT, Starodub AN, Horn L, Scheff RJ, Bardia A, Messersmith WA, Berlin J, Ocean AJ, Govindan SV, Maliakal P, Mudenda B, Wegener WA, Sharkey RM, Goldenberg DM, Camidge DR. Heist RS, et al. Among authors: goldenberg dm. J Clin Oncol. 2017 Aug 20;35(24):2790-2797. doi: 10.1200/JCO.2016.72.1894. Epub 2017 May 26. J Clin Oncol. 2017. PMID: 28548889 Clinical Trial.
750 results